SABR Offers New Hope for Older Patients With Inoperable Kidney Cancer
SAN DIEGO — Stereotactic ablative body radiotherapy (SABR) was an effective, noninvasive strategy for treating primary renal cell carcinoma (RCC) in patients who were not suitable for surgery, according to the FASTRACK II trial. In the prospective, phase II study of 70 patients, none had local progression of kidney cancer during the trial lifetime (median […]
SABR for Oligometastatic Cancer Turns in ‘Acceptable’ Rates of Toxicity
Stereotactic ablative radiotherapy (SABR) treatment for oligometastatic or oligoprogressive cancer appeared to come with “acceptable” rates of toxic effects, according to SABR-5 study results. Among a population of 381 patients in the phase II trial, and with a median follow-up of 25 months, rates of grade 2 or greater toxic effects were observed in 18.6%, […]
Single- or Multi-Fraction SABR for Lung Oligometastases?
Both single-fraction and multifraction stereotactic ablative body radiotherapy (SABR) had acceptable safety and comparable efficacy for patients with pulmonary oligometastases, according to results from a phase II randomized trial. The primary endpoint of grade 3 or higher adverse events (AEs) related to treatment within 1 year of SABR was similar between the single-fraction arm (5%) […]